Repositioning ‘old’ drugs to treat rare diseases: arguing from the mechanism of action

Repositioning ‘old’ drugs to treat rare diseases: arguing from the mechanism of action

Authors

  • Marjolein Drent ILD Center of Excellence, St. Antonius Hospital, Nieuwegein &
  • Aalt Bast Department of Pharmacology and Toxicology, Faculty of Health, Medicine and Life Sciences, University Maastricht
  • Hans-peter Bootsma Department of Pharmacology, Hospital Gelderse Vallei, Ede
  • Vera Deneer 5Department of Clinical Pharmacy, St. Antonius Hospital, Nieuwegein

Keywords:

histiocytosis-X, orphan drugs, pharmacological treatment, rare disease

Abstract

NA

Downloads

Published

01-08-2016

Issue

Vol. 33 No. 2 (2016)

Section

Letter to Editor

License

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.

 

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

1.
Drent M, Bast A, Bootsma H- peter, Deneer V. Repositioning ‘old’ drugs to treat rare diseases: arguing from the mechanism of action. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. 2016 Aug. 1 [cited 2025 Jun. 22];33(2):191-4. Available from: https://mattioli1885journals.com/index.php/sarcoidosis/article/view/4806